

**October 4, 2024**

**Addition of the following 2 Drugs to High-Cost Specialty Drug (BIO) Reinsurance coverage**

AHCCCS Financial Review Committee has approved the following Drugs for High-Cost Specialty Drug Reinsurance effective 10/01/2024:

**Vimzin** - for the treatment of Morquio syndrome.

**Strensiq -** for treatment of childhood hypophosphatasia.